Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-27T02:06:47.336Z Has data issue: false hasContentIssue false
  • English
  • Français

CPK levels and neuroleptic malignant syndrome

Published online by Cambridge University Press:  02 January 2018

Sheelah James
Sheelah James*
Affiliation:
Barnsley Hall Hospital, Stourbridge Road, Bromsgrove B61 0EX
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
The British Journal of Psychiatry , Volume 155 , Issue 4 , October 1989 , pp. 567
Copyright
Copyright © Royal College of Psychiatrists 1989 

References

Gledhill, R. F., Van Der Merwe, C. A., Greyling, M. et al (1988) Race-gender differences in serum creatine kinase activity: a study among South Africans. Journal of Neurology, Neurosurgery & Psychiatry, 51, 301–304 Google Scholar
Goode, D. J., Meltzer, H. Y., Morretti, R. et al (1979) The relationship between wrist monitored motor activity and serum CPK activity in psychiatric in-patients. British Journal of Psychiatry, 135, 62–66.Google Scholar
Kumar, A., Upadhyaya, G. L. & Trivedi, J. K. (1984) Serum CPK levels in schizophrenics and their first degree relatives. Indian Journal of Physiology and Pharmacology, 28, 128–132.Google ScholarPubMed
Meltzer, H. Y. & Holy, P. A. (1974) Black-white differences in serum creatine phosphokinase (CPK) activity. Clinica Chimica Acta, 54, 215–224.Google Scholar
Paasuke, R. T. & Brownell, A. K. (1986) Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia. Journal of the American Medical Association. 255, 769–771.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.